Thursday, January 12, 2012
Acomplia- a Growing Threat to Obesity
It’s always wise to plan a health diet by quickly calculating your health statistics and target. A planned diet health schedule with a proper medication plays a vital role in our weight loss program and keeps a count on our calories. Weight loss with Acomplia has worked out for many over weight people and can work for you too. Acomplia diet pills can be used by virtually any age group and by individuals of any activity level. Popularly known as Rimonabant, Acomplia is becoming a wonder drug for treating overweight significantly. Developed by French pharmaceutical company Sanofi- Aventis is successful in showing immense promise to majority of people suffering from obesity or overweight. So far the simple perspective of weight loss was through dieting and exercising vigorously. But in most cases the results proved to be mere temporary. But medically it has been proved successfully that if Acomplia goes along with your diet and exercise, the results can be magical. Clinical trials proved that 35% of patients on Acomplia (Rimonabant) lost 10%-12% of their body weight and kept their weight down for more than 2 years which is a record as no other diet pill has managed to keep a person’s weight for so long. Most interestingly, according to studies, apart from lowering body mass, it is believed to help a person by stopping his or her’s urges for nicotine. So it is believed to provide dual benefit to its users. Now let us see how it’s happen. There are various nerve receptors called CB1 receptors in our brain as well as our fat cells. The signals from these receptors are responsible to make a body hungry and often increase the urge for smoking. Acomplia blocks the signals of these receptors and stops our urges to over eat. Acomplia have consistently provided quality results and lasting benefits. It allows us to live at our own pace and doesn’t allow us to slack off. FDA is continuously studying and observing its affects especially on its smoking cessation quality. And once approved it is sure to rule the overweight market for the dual benefits associated with it.